で公開中です！詳しく見る

Scholar Rock

SRRK

時価総額 $48.6億

39.90 USD

-0.74

1.82%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

39.90

0.00

0%

1日

-1.82%

5日間

-4.86%

1か月

-19.18%

3か月

-22.87%

6か月

-20.2%

年初来

-6.78%

1年

35.53%

5年間

50.45%

10年間

157.42%

概要： Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

従業員数： 289

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 22.6%

ニュートラル 64.5%

ネガティブ 12.9%

ニュートラル

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 17,461 shares of common stock and inducement restricted stock units, covering an aggregate of 43,559 shares of its common stock. The awards are subject to all terms and conditions and other provisi.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ニュートラル

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European Medicines Agency (EMA). Informed by ongoing dialogue.

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

ニュートラル

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

ニュートラル

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hired employees, consisting of inducement stock options to purchase an aggregate of 23,801 shares of common stock and inducement restricted stock units, covering an aggregate of 59,301 shares of its common stock. The awards are subject to all terms and conditions and other provision.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ポジティブ

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD [apitegromab] for SMA in patients ≥2 years old. SRRK targets a $2B+ market opportunity in SMA, with expansion potential into younger populations, subcutaneous formulations, and new indications like FSHD. Regulatory catalysts include planned MAA resubmission in Europe and anticipated JNDA filing in Japan by year-end 2026, leveraging a validated manufacturing facility.

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

ネガティブ

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

ニュートラル

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

ポジティブ

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock (NASDAQ:SRRK) for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older.

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

ポジティブ

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Scholar Rock on Monday set a list ‌price of $11,659 per single-use vial for its newly approved spinal muscular ⁠atrophy drug, the first therapy that directly targets muscle loss in patients with the rare genetic disorder.

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

ポジティブ

Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children and adults with Spinal Muscular Atrophy (SMA).

Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています